President Donald Trump has signed an executive order accelerating research for certain psychedelic drugs used to treat mental health disorders. The order also directs the Food and Drug Administration (FDA) to expedite its review of new treatments. This move is specifically aimed at veterans who are suffering from symptoms of anxiety and depression. The move applies to certain drugs, including psychedelics, that are currently in the advanced stages of clinical trials. The administration will also consider Ibogaine, a psychedelic drug used in other countries to treat PTSD, as part of its efforts to include this drug under the Right to Try Act.